


Johns Hopkins ABX Guide













When looking at antibiotic:



When Looking at Diagnosis:



Basis for recommendation

 Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis. 2015;61(8):e26-46. [PMID:26229122]

Comment: Updated clinical practice guidelines for vertebral osteomyelitis treatment in adults.

References

 Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019;380(5):425-438. [PMID:30699315]

Comment: Much discussed and debated first major RCT of oral vs IV antibiotics for bone and joint infections. Showing rates of relapse similar in two groups. However, implications around close monitoring of patients on oral antibiotics vs OPAT continue to be discussed. Few MRSA infections were At the bottom of each page, they list reference and the resources that are the Basis for recommendation – the PMID is listed, making it easy to access literature/guidelines for additional information

When Looking at Pathogen:

Pseudomonas aeruginosa

MICROBIOLOGY CLINICAL SITES OF INFECTION TREATMENT

General principles

Chemotherapy

Selected Drug Comments

OTHER INFORMATION

Basis for recommendation References

Media

Pseudomonas aeruginosa

Fig 1

■ Johns Hopkins ABX Guide → Pathogens →
Bacteria



Pseudomonas aeruginosa

Lisa A. Spacek, M.D., Ph.D.

MICROBIOLOGY

- Gram-negative non-fermenting, motile bacillus [Fig 1]; known for blue-green pus due to pyocyanin and pyoverdin pigments.
- Non-fastidious organism; inhabits a variety of environments including soil and water, i.e., hot tubs, sinks, water faucets, respirators, disinfectants, and contact lens cleaning solution.
- Grows on a wide variety of media. Clinical isolates usually render smooth colonies on plates [Fig 2].
- · Produces biofilm, toxins, and proteases.
- Drug resistance mechanisms include multiple pathways: chromosomal and inducible betalactamases, active efflux pumps, acquired genes and plasmid-mediated ESBLs (TEM, SHV, CTX-M), and altered permeability.[8][13]
 - Carbapenem-resistance mechanisms include:
 - Loss of outer membrane porin D (OprD) results in resistance to carbapenems.
 - The combined loss of OprD in combination with another mechanism, i.e., overexpression of AmpC beta-lactamase OR overexpression of efflux pumps, is a major determinant of resistance to carbapenems.[12]
 - Production of carbapenemases, esp. Ambler class B metallo-beta-lactamases (NDM, VIM, IMP).[4]
 - Clinical utility of rapid molecular diagnostic platforms to detect genotype resistance to betalactam/beta-lactamase inhibitor combinations is limited by the complexity of non-tested determinants of beta-lactam resistance, such as OprD changes and drug efflux systems.[3]

CLINICAL

- Usually a nosocomial, opportunistic pathogen—especially in the setting of immunocompromised host or foreign body, central line, or urinary catheter.
 - · Chronic colonizer of cystic fibrosis (CF) lung.
 - Agent of pneumonia (ventilator-associated), UTI, bacteremia (neutropenia), postneurosurgical meningitis, post-surgical infections, and hot-tub folliculitis.
 - Ecthyma gangrenosum: infarcted skin lesions due to vascular invasion with heavy organism burden is uncommon, and seen mostly in immunosuppressed or critically ill patients.
- Risk factors include immunosuppression, diabetes mellitus, skin burns, cystic fibrosis, neutropenia, complement deficiency, and AIDS.
- Multidrug resistance (MDR): likely in those with recent abx therapy (past 90d), hospital stay > 4d, high rate of abx resistance associated with residence in a chronic care facility.[17]
- Historically associated with high mortality in the setting of.
 - · Febrile neutropenia, bacteremia, pneumonia, and skin and soft tissue infections
 - · Infected burn wounds with heavy bacterial growth in burn eschar

SITES OF INFECTION

- · Respiratory: pneumonia (nosocomial, CF, AIDS), lung abscesses
- Cli LTII and an artist for a state of the st

Selected Drug Comments

- Cefiderocol is a synthetic conjugate with cephalosporin moiety to inhibit cell wall synthesis PLUS a siderophore moiety to enter cells via active iron transporters.[9]
- Taniborbactam is a next-generation β-lactamase inhibitor with direct inhibitory activity against Ambler class A, B, C, and D enzymes. Combination of cefepime-taniborbactam demonstrates broad-spectrum rescue of cefepime activity against carbapenem-resistant P. aeruginosa.[2]

Drug	Recommendation
Amikacin	A traditional second drug used with anti-pseudomonal β-lactams for wider empiric coverage. Renal (reversible) toxicity associated with a greater duration of treatment and higher doses. Monitor for otic (irreversible) toxicity which may be seen with > 3d of therapy. Has had the best susceptibility coverage of typically used aminoglycosides against P. aeruginosa at many institutions, although plazomicin may now be the leader.
Aztreonam	Anti-pseudomonal monobactam. Increasing resistance may limit effectiveness.
Cefepime	Fourth-generation cephalosporin with anti-pseudomonal and anti-S.

Grapherence® [†18] Search PRIME PubMed Related Topics Mastoiditis Colistimethate (colistin) Otitis Externa Norfloxacin Ceftolozane/tazobac Polymyxin B Paronychia Ticarcillin + Clavulanic Acid Cardiovascular Device Infections more.

Provides helpful clinical information and under microbiology, will give you an easy to understand review of any potential resistance that can be helpful.

The Selected Drugs
Comments Section can
provide some helpful
information for each
potential antibiotic that can
help with clinical decision
making